Watchlist Price Alert

Relay Therapeutics Inc. (RLAY)

NASDAQ: RLAY · Real-Time Price · USD

3.02

0.07 (2.37%)

At close: May 08, 2025, 1:08 PM

2.37% (1D)

Bid	3.01
Market Cap	514.02M
Revenue (ttm)	7.68M
Net Income (ttm)	-333.39M
EPS (ttm)	-2.2
PE Ratio (ttm)	-1.37
Forward PE	-1.35
Analyst	Buy

Ask	3.02
Volume	1,662,336
Avg. Volume (20D)	2,553,434
Open	2.94
Previous Close	2.95
Day's Range	2.71 - 3.07
52-Week Range	1.77 - 10.72
Beta	1.66

About RLAY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RLAY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RLAY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Relay Therapeutics has released their quartely earnings on May 5, 2025:

Revenue of $7.68M exceeds estimates by $7.67M, with -23.26% YoY decline.

EPS of -0.46 exceeds estimates by 0.05, with 25.81% YoY growth.

Why Price Moved

2 days ago

-5.12%

Relay Therapeutics shares are trading lower follow... Unlock content with Pro Subscription

4 months ago

+12.42%

Relay Therapeutics shares are trading higher after the company announced updated interim clinical data for RLY-2608.

News

3 weeks ago · zacks.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.

3 weeks ago · seekingalpha.com

Relay Therapeutics: Trying To Find That Right Price

Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, sho...

2 months ago · zacks.com

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

2 months ago · seekingalpha.com

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q...